{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T15:23:34Z","timestamp":1782660214170,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:00:00Z","timestamp":1564358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:00:00Z","timestamp":1564358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011957","name":"Takeda Pharmaceutical Company Limited | Takeda Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In this phase I\/II trial, BID, bendamustine (70, 80, or 90\u2009mg\/m<jats:sup>2<\/jats:sup>), ixazomib (4\u2009mg), and dexamethasone (40\u2009mg), was administered to 28 patients with relapsed and\/or refractory multiple myeloma (RRMM) exposed to bortezomib and lenalidomide and refractory to at least one. A 3\u2009+\u20093 dose escalation based on dose-limiting toxicities (DLTs) was employed in phase I (total 15); 2\/6 patients developed DLTs (neutropenia and thrombocytopenia) at dose level 3 establishing the recommended phase II dose as bendamustine 80\u2009mg\/m<jats:sup>2<\/jats:sup>, ixazomib 4\u2009mg, and dexamethasone 40\u2009mg. The median age was 67 years (range, 42\u201372), and 43% were females. Patients received a median of 4 (range, 4\u20139) prior lines of therapy, of which ~50% were double refractory. In phase II, total 19 patients were treated. With a median follow-up of 17 months, 11% achieved very good partial response, 50% achieved partial response, and 27% achieved stable disease. Median progression free (PFS) and overall (OS) survival were 5.2 months (95% CI, 1.96\u20138.3) and 23.2 months (95% CI 16.3\u201330.07). The most frequent adverse events were anemia, thrombocytopenia, leukopenia, nausea, diarrhea, and infections. Peripheral neuropathy was infrequent. BID is a well-tolerated and effective combination therapy for patients with RRMM.<\/jats:p>","DOI":"10.1038\/s41408-019-0219-3","type":"journal-article","created":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T15:02:52Z","timestamp":1564412572000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Phase I\/II trial of bendamustine, ixazomib, and dexamethasone in relapsed\/refractory multiple myeloma"],"prefix":"10.1038","volume":"9","author":[{"given":"Binod","family":"Dhakal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Arce-Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirav N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Gauger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Keaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Hari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,29]]},"reference":[{"key":"219_CR1","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar, S. K. et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28, 1122\u20131128 (2014).","journal-title":"Leukemia"},{"key":"219_CR2","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/leu.2017.185","volume":"31","author":"A D\u2019Souza","year":"2017","unstructured":"D\u2019Souza, A. et al. Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004\u20132014. Leukemia 31, 1998\u20132000 (2017).","journal-title":"Leukemia"},{"key":"219_CR3","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","volume":"27","author":"BD Cheson","year":"2009","unstructured":"Cheson, B. D. & Rummel, M. J. Bendamustine: rebirth of an old drug. J. Clin. Oncol. 27, 1492\u20131501 (2009).","journal-title":"J. Clin. Oncol."},{"key":"219_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.seminhematol.2011.03.001","volume":"48","author":"LM Leoni","year":"2011","unstructured":"Leoni, L. M. The evolving role of bendamustine in lymphoid malignancy: understanding the drug and its mechanism of action-introduction. Semin. Hematol. 48, S1\u2013S3 (2011).","journal-title":"Semin. Hematol."},{"key":"219_CR5","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1053\/j.seminhematol.2011.03.004","volume":"48","author":"MJ Rummel","year":"2011","unstructured":"Rummel, M. J. & Gregory, S. A. Bendamustine\u2019s emerging role in the management of lymphoid malignancies. Semin. Hematol. 48, S24\u2013S36 (2011).","journal-title":"Semin. Hematol."},{"key":"219_CR6","first-page":"1287","volume":"90","author":"S Knop","year":"2005","unstructured":"Knop, S. et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 90, 1287\u20131288 (2005).","journal-title":"Haematologica"},{"key":"219_CR7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1365-2141.2011.08887.x","volume":"156","author":"E Grey-Davies","year":"2012","unstructured":"Grey-Davies, E. et al. Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma. Br. J. Haematol. 156, 552\u2013555 (2012). author reply 5.","journal-title":"Br. J. Haematol."},{"key":"219_CR8","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1182\/blood-2011-12-395715","volume":"119","author":"S Lentzsch","year":"2012","unstructured":"Lentzsch, S. et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1\/2 open-label, dose escalation study. Blood 119, 4608\u20134613 (2012).","journal-title":"Blood"},{"key":"219_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0104-5","volume":"8","author":"D Sivaraj","year":"2018","unstructured":"Sivaraj, D. et al. Bendamustine, pomalidomide, and dexamethasone for relapsed and\/or refractory multiple myeloma. Blood Cancer J. 8, 71 (2018).","journal-title":"Blood Cancer J."},{"key":"219_CR10","doi-asserted-by":"crossref","unstructured":"Gramatzki Mea. Carfilzomib in combination with bendamustine and dexamethasone (CBd) in relapsed and\/or refractory patients with multiple myeloma: the phase I\/II EMN09 study. Blood, 128, 3334 (2016).","DOI":"10.1182\/blood.V128.22.3334.3334"},{"key":"219_CR11","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1182\/blood-2013-08-521468","volume":"123","author":"H Ludwig","year":"2014","unstructured":"Ludwig, H. et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 123, 985\u2013991 (2014).","journal-title":"Blood"},{"key":"219_CR12","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","volume":"70","author":"E Kupperman","year":"2010","unstructured":"Kupperman, E. et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 70, 1970\u20131980 (2010).","journal-title":"Cancer Res."},{"key":"219_CR13","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","volume":"124","author":"SK Kumar","year":"2014","unstructured":"Kumar, S. K. et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma. Blood 124, 1047\u20131055 (2014).","journal-title":"Blood"},{"key":"219_CR14","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","volume":"15","author":"SK Kumar","year":"2014","unstructured":"Kumar, S. K. et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study. Lancet Oncol. 15, 1503\u20131512 (2014).","journal-title":"Lancet Oncol."},{"key":"219_CR15","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1182\/blood-2016-05-717769","volume":"128","author":"SK Kumar","year":"2016","unstructured":"Kumar, S. K. et al. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood 128, 2415\u20132422 (2016).","journal-title":"Blood"},{"key":"219_CR16","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau, P. et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for multiple myeloma. N. Engl. J. Med. 374, 1621\u20131634 (2016).","journal-title":"N. Engl. J. Med."},{"key":"219_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau, P. et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 12, 431\u2013440 (2011).","journal-title":"Lancet Oncol."},{"key":"219_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4519","volume":"4","author":"AJ Waxman","year":"2018","unstructured":"Waxman, A. J. et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 4, e174519 (2018).","journal-title":"JAMA Oncol."},{"key":"219_CR19","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"219_CR20","doi-asserted-by":"publisher","first-page":"6907","DOI":"10.1158\/1078-0432.CCR-08-0388","volume":"14","author":"G Roue","year":"2008","unstructured":"Roue, G. et al. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin. Cancer Res. 14, 6907\u20136915 (2008).","journal-title":"Clin. Cancer Res."},{"key":"219_CR21","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld, P. et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J. Clin. Oncol. 30, 2946\u20132955 (2012).","journal-title":"J. Clin. Oncol."},{"key":"219_CR22","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/leu.2013.335","volume":"28","author":"AK Nooka","year":"2014","unstructured":"Nooka, A. K. et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia 28, 690\u2013693 (2014).","journal-title":"Leukemia"},{"key":"219_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/bjh.12129","volume":"160","author":"JR Berenson","year":"2013","unstructured":"Berenson, J. R. et al. Phase I\/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br. J. Haematol. 160, 321\u2013330 (2013).","journal-title":"Br. J. Haematol."},{"key":"219_CR24","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","volume":"17","author":"D Chauhan","year":"2011","unstructured":"Chauhan, D. et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin. Cancer Res. 17, 5311\u20135321 (2011).","journal-title":"Clin. Cancer Res."},{"issue":"15_suppl","key":"219_CR25","doi-asserted-by":"publisher","first-page":"8013","DOI":"10.1200\/JCO.2017.35.15_suppl.8013","volume":"35","author":"James R. Berenson","year":"2017","unstructured":"Berenson, J. R. C. A. et al. Replacement of ixazomib for relapsed\/refractory multiple myeloma patients refractory to a bortezomib or carfilzomib-containing combination therapy. J. Clin. Oncol. 35, 8013\u20138013 (2017).","journal-title":"Journal of Clinical Oncology"},{"key":"219_CR26","doi-asserted-by":"crossref","unstructured":"Reu, F. J. V. J. et al. A Phase I Study of Ixazomib in combination with Panobinostat and Dexamethasone in patients with relapsed or refractory multiple myeloma. Blood 126, 4221 (2015).","DOI":"10.1182\/blood.V126.23.4221.4221"},{"key":"219_CR27","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1182\/blood-2017-06-791228","volume":"130","author":"H Avet-Loiseau","year":"2017","unstructured":"Avet-Loiseau, H. et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed\/refractory myeloma patients. Blood 130, 2610\u20132618 (2017).","journal-title":"Blood"},{"issue":"7","key":"219_CR28","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41375-018-0038-8","volume":"32","author":"Amrita Krishnan","year":"2018","unstructured":"Krishnan, A. et al. Phase I\/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed\/refractory multiple myeloma. Leukemia 32, 1567\u20131574 (2018).","journal-title":"Leukemia"},{"key":"219_CR29","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","volume":"130","author":"A Chari","year":"2017","unstructured":"Chari, A. et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma. Blood 130, 974\u2013981 (2017).","journal-title":"Blood"},{"key":"219_CR30","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1182\/bloodadvances.2018028027","volume":"3","author":"TM Mark","year":"2019","unstructured":"Mark, T. M. et al. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. Blood Adv. 3, 603\u2013611 (2019).","journal-title":"Blood Adv."},{"key":"219_CR31","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","volume":"126","author":"JJ Shah","year":"2015","unstructured":"Shah, J. J. et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood 126, 2284\u20132290 (2015).","journal-title":"Blood"},{"key":"219_CR32","doi-asserted-by":"crossref","unstructured":"Dimopoulos M. A. (eds) Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial (ASH, San Diego, 2018).","DOI":"10.1182\/blood-2018-99-112079"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0219-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0219-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0219-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T16:13:07Z","timestamp":1671207187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0219-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,29]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8]]}},"alternative-id":["219"],"URL":"https:\/\/doi.org\/10.1038\/s41408-019-0219-3","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,29]]},"assertion":[{"value":"25 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.D. has served on the advisory board for Takeda and Amgen. P.H. has received grant support and consulting honoraria from Takeda. A.D.\u2014institutional funding: Amgen, Celgene, Merck, Prothena, Takeda; Consultancy: Prothena; Advisory board- Pfizer. M.H. reports Research Support\/Funding: Takeda Pharmaceutical Company; Otsuka Pharmaceutical; Spectrum Pharmaceuticals; Astellas Pharma. Consultancy: MedImmune LLC; Janssen R &D; Incyte Corporation; ADC Therapeutics; Cellerant Therapeutics; Celgene Corporation; Pharmacyclics & DOVA Oncology. Speaker\u2019s Bureau: Celgene Corporation (Inactive); Sanofi Genzyme. N.N.S. reports research funding from Lentigen, A miltenyi biotech company. He has served on the advisory boards for Kite, Juno, and Cellectar. The remaining authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"56"}}